Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.

ABSTRACT: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the axial skeleton. All patients receive conservative management measures which include physiotherapy, patient education and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Those with significant active disease will require escalation of their treatment with the use of biologics. Currently, there are five approved TNF inhibitors and two approved IL-17 inhibitors for use in axSpA. However, despite this up to 40% of patients do not respond or are intolerant to current available treatment. This leaves a significant number of patients with uncontrolled disease and unmet need for additional therapies. Though many drug classes have been trialed for axSpA they show poor efficacy; however, over the

SUBMITTER: Tahir H 

PROVIDER: S-EPMC8269276 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature